Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T-siHER2-NP
- Development stage
- Preclinical
- Lead developer
- PDX Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**T-siHER2-NP** is a preclinical, trastuzumab-targeted mesoporous silica nanoparticle formulation for drug-resistant **HER2-positive breast cancer**. The construct uses trastuzumab to bind HER2-positive tumor cells and promote cellular uptake while delivering a small interfering RNA directed against **ERBB2/HER2** messenger RNA, resulting in HER2 protein knockdown and suppression of HER2-dependent signaling. In preclinical HER2-positive breast cancer models, the formulation showed activity against tumors resistant to trastuzumab and taxanes, including HCC1954 and BT474-TR models. It was developed from nanoparticle work at Oregon Health & Science University and is being advanced by PDX Pharmaceuticals.
- Other names
- T-siHER2 d75-NPT-siHER-2 d75-NPT-siHER 2 d75-NP
02
Targets
Erb-b2 receptor tyrosine kinase 2 messenger RNAERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on T-siHER2-NP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T-siHER2-NP.